S137 ESTRO 38Gefitinib (4), Crizotinib (3), Ceritinib (1), Alectinib (1), Afatinib (1), Lorlatinib (1), Nintedanib (1), Rociletinib (1).IT or TT was started after the completion of RS in 18 patients; in the remaining cases (n=12), IT or TT was begun before RS (IT or TT was interrupted for a median period of seven days from RS in the majority of patients).Median follow-up was 12 months.One patient developed G1 radionecrosis after 18 months from RS.No G3 toxicity was observed.Median L-PFS and D-PFS were 10.6 and 7 months, respectively.Conclusion RS for BM may be safely associated with IT or TT in patients with NSCLC.Prospective studies are needed to confirm our results.
Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Sandhu, Ben Tran, Arun Azad, Jeremy Lewin, Katharine Cuff, Nitika Neha, Duncan Colyer, Paul J. Neeson, Howard Liu, Sarat Chander, Daniel Moon, Jeremy Goad, Declan G. Murphy, Nathan Lawrentschuk, David Pryor
Shankar Siva, Mathias Bressel, Mark Shaw, Sarat Chander, Sherene Loi, David Pryor, Shahneen Sandhu, Jennifer Mooi, Dasantha Jayamanne, Thomas Eade, Nathan Lawrentschuk, Declan Murphy, Jeremy Lewin, Ben Tran, Farshad Foroudi
Shankar Siva, Mathias Bressel, Mark Shaw, Sarat Chander, Sherene Loi, David Pryor, Shahneen Sandhu, Jennifer Mooi, Dasantha Jayamanne, Thomas Eade, Nathan Lawrentschuk, Declan Murphy, Jeremy Lewin, Ben Tran, Farshad Foroudi
María‐Victoria Mateos, Jesús G. Berdeja, Meletios A Dimopoulos, David S. Siegel, P. Joy Ho, Mei Huang, Martina Sersch, Anita Zahlten‐Kumeli, Amy Kimball, Katja Weisel
Discussion(0)
No comments yet. Be the first to comment.